Andrew Gengos - 18 May 2023 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Officer
Signature
/s/ Mark Worthington, Attorney-in-fact for Andrew Gengos
Issuer symbol
ATHA
Transactions as of
18 May 2023
Net transactions value
$0
Form type
4
Filing time
22 May 2023, 17:53:19 UTC
Previous filing
24 Feb 2022
Next filing
06 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Options (right to buy) Award $0 +400,000 $0.000000 400,000 18 May 2023 Common Stock 400,000 $2.84 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-third (1/3) of the shares subject to the option shall be scheduled to vest on May 18, 2024, the one (1) year anniversary of May 18, 2023, and the remaining shares subject to the option shall be scheduled to vest monthly over the next 36 months on the 18th of each month, subject to the Reporting Person continuing to be a Service Provider (as defined in Athira Pharma, Inc.'s 2020 Equity Incentive Plan) through the applicable vesting dates, as follows: one-third (1/3) of the shares subject to the option shall be scheduled to vest in equal monthly amounts over the next 12 months; one-sixth (1/6) of the shares subject to the option shall be scheduled to vest in equal monthly amounts over the subsequent 12 months; and the remaining one-sixth (1/6) of the shares subject to the option shall be scheduled to vest in equal monthly amounts over the final 12 months.

Remarks:

Chief Financial Officer and Chief Business Officer